The Digital Medicine Society (DiMe) introduced it’s partnering with Alcohol and Drug Companies (ADS), Duke University, Google Fitbit, Morse Clinics, North Carolina Central College, Ōura, ProofPilot, Triangle CERSI and the University of North Carolina at Chapel Hill (UNC).
The partnership goals to make use of information collected from client wearables to decrease opioid use dysfunction (OUD) fatalities by creating interventions to assist stop relapse.
In line with a 2023 National Survey on Drug Use and Health by the Substance Abuse and Psychological Well being Companies Administration (SAMHSA), amongst individuals aged 12 or older in 2023, 2.0 p.c (or 5.7 million individuals) had an opioid use dysfunction prior to now 12 months.
The companions will collaborate to explain and collect physiological indicators and conduct traits, together with coronary heart fee, insomnia, bodily inactivity and physiological stress, that may forecast relapse and be measured by wearable applied sciences.
Researchers will use smartphones to gather psychological well being traits equivalent to social isolation, patient-reported anxiousness and melancholy. The info factors practice a instrument to forestall opioid relapse.
The crew will proceed with analysis collectively led by Duke College’s BIG IDEAs Lab and enlist sufferers for a pilot examine to check the strategy and be sure that their strategies get hold of optimal-quality information to develop the relapse prevention instrument.
“OUD is a fancy problem, and complicated challenges require progressive collaboration and options,” Candice Taguibo, affiliate program director of DiMe, stated in an announcement.
“Our crew is working to include the numerous points at play for these going through OUD – psychological well being, social assist, remedy choices, funds, entry to know-how, social stigma, and extra – and construct a instrument that may meaningfully change the arc of OUD relapse and save 1000’s of lives.”
Shyamal Patel, senior vp of science at Oura, asserted that leveraging technological developments to develop evidence-based protocols for individuals dwelling with OUD will place these interventions for fulfillment.
“We’re proud to assist this examine by offering steady well being monitoring and personalised, data-driven insights. This may empower people to take proactive steps of their restoration, probably decreasing the burden on our overstretched public well being techniques and providing a vital instrument within the battle in opposition to the opioid epidemic,” Patel stated in an announcement.
THE LARGER TREND
In March, DiMe and Google Health launched a free online course for medical professionals, researchers, directors and innovators to be taught the fundamentals of generative AI, massive language fashions (LLMs) and the applied sciences’ use instances in healthcare.
The Generative AI for Healthcare course supplies stakeholders with an understanding of LLMs and their functions in healthcare. As well as, contributors will acquire insights into generative AI know-how, develop immediate engineering abilities and discover how AI can assist decision-making in scientific settings.
In 2024, researchers from South Korea constructed machine learning-based fashions that may predict temper episodes utilizing solely sleep and circadian rhythm information from wearable units.
The crew comprised researchers from the Institute for Fundamental Sciences (IBS), Korea Superior Institute of Science and Know-how (KAIST) and Korea College Faculty of Medication.
In a examine revealed in Nature’s Digital Medicine journal, the analysis crew first collected and analyzed 429 days’ price of sleep-wake information generated from Fitbit of 168 Korean sufferers with temper issues, together with main melancholy and bipolar issues.
The analysis crew extracted 36 sleep and circadian rhythm options from this dataset, which have been then utilized to coach fashions primarily based on the machine studying library XGBoost to foretell temper episodes.
The findings revealed that the predictive fashions achieved 80%, 98% and 95% accuracy in predicting depressive, manic and hypomanic episodes, respectively.
That very same 12 months, Oura closed a $200 million Series D funding round led by Fidelity Management & Research Company and Dexcom. The funding raised the corporate’s valuation to $5.2 billion.
In November 2024, Dexcom made a $75 million strategic investment in Oura and established a strategic partnership that enabled two-way information circulate between Dexcom’s steady glucose monitor (CGM) and the Oura Ring. The funding on the time introduced Oura’s valuation to greater than $5 billion.
Trending Merchandise
